Lupus erythematosus. Part II: Clinical picture, diagnosis and treatment;Lupus erythematodes. Teil II: Klinisches Bild, Diagnostik und Therapie

JDDG - Journal of the German Society of Dermatology

Volumn 12, Issue 4, 2014, Pages 285-304

  Ziemer, Mirjana ^a   Milkova, Linda ^a   Kunz, Manfred ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BELIMUMAB; CHLOROQUINE; CORTICOSTEROID; CYTOKINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; IMMUNOLOGIC FACTOR; SUNSCREEN;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; LUPUS ERYTHEMATOSUS; ORGAN SYSTEMS; SKIN MANIFESTATION; T LYMPHOCYTE; HUMAN; LUPUS ERYTHEMATOSUS, CUTANEOUS; PATHOLOGY;

ADRENAL CORTEX HORMONES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SUNSCREENING AGENTS;

EID: 84898796401     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12254_suppl     Document Type: Article

References (27)

1. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4(4): 471-5.
2. Albrecht J, Berlin JA, Braverman IM et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 2004; 13(11): 839-49.
3. Tsuchida T. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev 2009; 8(6): 453-5.
4. Kanda N, Tsuchida T, Watanabe T, Tamaki K. Clinical features of systemic lupus erythematosus in men. Characteristics of the cutaneous manifestations. Dermatology 1996;193(1): 6-10.
5. Parodi A, Rebora A. ARA and EADV criteria for classification of systemic lupus erythematosus in patients with cutaneous lupus erythematosus. Dermatology. 1997; 194(3): 217-20.
6. Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677-86.
7. Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2012; 166(3): 575-600.
8. Ackerman AB, Böer A, Bennin B, Gottlieb JG. Histologic Diagnosis of Inflammatory Skin Diseases. An Algorithmic Method Based on Pattern Analysis, 3 ed., New York: ArdorScribendi; 2005.
9. Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev 2009; 8(6): 467-73.
10. Biazar C, Sigges J, Patsinakidis N et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1 002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12(3): 444-54.
11. Ruland V, Haust M, Stilling RM et al. Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res (Hoboken) 2013; 65(5): 767-76.
12. Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010; 8(10): 829-44.
13. Marzano A, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18(11): 935-40.
14. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011; 65(6): e179-93.
15. Jemec GB, Ullman S, Goodfield M et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 2009; 161(6): 1365-70.
16. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011; 65(6): e195-213.
17. Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH. The use of glucocorticoids in Systemic Lupus Erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013; 12(5): 617-28.
18. Ruzicka T, Sommerburg C, Goerz G et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127(5): 513-18.
19. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011; 7(12): 718-29.
20. Islam MN, Hossain M, Haq SA et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis 2012; 15(1): 62-8.
21. Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002; 46(4): 600-3.
22. Wenzel J, Brahler S, Bauer R et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153(1): 157-62.
23. Miyawaki S, Nishiyama S, Aita T, Yoshinaga Y. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus. Mod Rheumatol 2013; 23(4): 659-66.
24. Kreuter A, Tomi NS, Weiner SM et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007; 156(6): 1321-7.
25. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7(6): 349-59.
26. Chan VS, Tsang HH, Tam RC et al. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol 2013; 10(2): 133-42.
27. Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol 2013; 148(3): 359-68.